Sign Out
Hypersensitivity to domperidone or any ingredients in the product.
Prolactin-releasing pituitary tumor (prolactinoma).
Patients with gastrointestinal hemorrhage, mechanical obstruction or perforation, or when stimulation of gastric motility could be harmful.
Patients with moderate or severe hepatic impairment.
Patients with significant electrolyte disturbances (hypokalemia, hyperkalemia, hypomagnesemia) or bradycardia; these are known to be conditions increasing the proarrhythmic risk.
Conditions where the cardiac conduction intervals are impaired or could be affected and underlying cardiac diseases as congestive heart failure, when co-administered with QT-prolonging drugs or potent CYP3A4 inhibitors (see INTERACTIONS).
